Constitutive activity and ligand selectivity of human, guinea pig, rat, and canine histamine H2 receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 321, Issue 3, 2007, Pages 983-995

  Preuss, Hendrik ^a   Ghorai, Prasanta ^a,b   Kraus, Anja ^a   Dove, Stefan ^a   Buschauer, Armin ^a   Seifert, Roland ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; GUANOSINE TRIPHOSPHATASE; HISTAMINE H2 RECEPTOR; HYBRID PROTEIN; METIAMIDE;

ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; INSECT CELL; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ADENYLATE CYCLASE; ANIMALS; BACULOVIRIDAE; CELL LINE; CELL MEMBRANE; DOGS; GTP PHOSPHOHYDROLASES; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; GUINEA PIGS; HISTAMINE; HISTAMINE AGONISTS; HISTAMINE H2 ANTAGONISTS; HUMANS; LIGANDS; METIAMIDE; RATS; RECEPTORS, HISTAMINE H2; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; SPECIES SPECIFICITY; SPODOPTERA; TRANSFECTION;

EID: 34248546193     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.120014     Document Type: Article

References (41)

1. 2 receptor. J Neurochem 71:799-807.
2. 2 receptor. Mol Pharmacol 57:890-898.
3. Ballesteros JA, Jensen AD, Liapakis G, Rasmussen SG, Shi L, Gether U, and Javitch JA (2001) Activation of the β2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J Biol Chem 276:29171-29177.
4. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
5. 2 receptor ligands. Mini Rev Med Chem 4:941-954.
6. 1-receptor agonists. J Med Chem 43:1071-1084.
7. 2 receptors expressed in Sf9 and COS7 cells. FEBS Lett 409:283-286.
8. 2 receptor by site-directed mutagenesis: N-glycosylation is not vital for its action. Biochem J 310:553-558.
9. 2 receptor with low basal activity, is resistant to upregulation upon antagonist exposure. Pharmacogenomics J 1:78-83.
10. 2 receptor. J Biol Chem 267:20840-20843.
11. 2 receptor. Biochem Biophys Res Commun 178:1386-1392.
12. 2 receptor. Proc Natl Acad Sci USA 88:429-433.
13. 2 Receptor Agonists with Reduced Basicity. Ph.D. thesis. University of Regensburg, Regensburg, Germany.
14. sα proteins in Sf9 insect cells: limitations in comparison with fusion proteins. Biochim Biophys Acta 1613:101-114.
15. Hill SJ, Ganellin CR, Timmerman H, Schwartz JC, Shankley NP, Young JM, Schunack W, Levi R, and Haas HL (1997) International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev 49:253-278.
16. q- proteins: limitations of Sf9 cells for the analysis of receptor/Gqprotein coupling. J Neurochem 80:678-696.
17. Kararli TT (1995) Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 16:351-380.
18. 2-receptor with guanidine-type agonists. Mol Pharmacol 60:1210-1225.
19. Kenakin T (2001) Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 15:598-611.
20. Kopin AS, McBride EW, Schaffer K, and Beinborn M (2000) CCK receptor polymorphisms: an illustration of emerging themes in pharmacogenomics. Trends Pharmacol Sci 21:346-353.
21. Lefkowitz RJ, Cotecchia S, Samama P, and Costa T (1993) Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci 14:303-307.
22. Milligan G (2000) Insights into ligand pharmacology using receptor-G-protein fusion proteins. Trends Pharmacol Sci 21:24-28.
23. 2 receptor. II. Theoretical investigations of histamine binding to receptor models of the seven α-helical transmembrane domain. J Comput Aided Mol Des 10:479-489.
24. Ostrom RS and Insel PA (2004) The evolving role of lipid rafts and caveolae in G protein-coupled receptor signaling: implications for molecular pharmacology. Br J Pharmacol 143:235-245.
25. 2 receptor determines the species selectivity of guanidine-type agonists and increase constitutive activity. J Pharmacol Exp Ther 321:975-982.
26. Prezeau L, Gomeza J, Ahern S, Mary S, Galvez T, Bockaert J, and Pin JP (1996) Changes in the carboxyl-terminal domain of metabotropic glutamate receptor 1 by alternative splicing generate receptors with differing agonist-independent activity. Mol Pharmacol 49:422-429.
27. 2-receptor gene. Biochem Biophys Res Commun 179:1470-1478.
28. 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268:4625-4636.
29. sα fusion protein. Eur J Biochem 255:369-382.
30. Seifert R and Wenzel-Seifert K (2002) Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn-Schmiedeberg's Arch Pharmacol 366:381-416.
31. 1-receptor. J Pharmacol Exp Ther 305:1104-1115.
32. Seifert R, Wenzel-Seifert K, and Kobilka BK (1999) GPCR-Gα fusion proteins: molecular analysis of receptor-G-protein coupling. Trends Pharmacol Sci 20:383-389.
33. sα has properties of a constitutively active receptor. J Biol Chem 273:5109-5116.
34. 2 receptor contains positive and negative signals important for signal transduction and receptor down-regulation. J Neurochem 67:1791-1800.
35. 2 adrenoceptor. Kinetic evidence for intermediate conformational states. J Biol Chem 279:686-691.
36. 2 receptor: gene cloning, tissue expression and chromosomal localization of its human counterpart. Biochem Biophys Res Commun 211:570-577.
37. 2A receptor by disruption of the ionic lock of the arginine cage. Int J Quantum Chem 88:65-75.
38. sα splice variants. Biochem Pharmacol 64:9-20.
39. Wenzel-Seifert K and Seifert R (2003) Functional differences between human formyl peptide receptor isoforms 26, 98, and G6. Naunyn-Schmiedeberg's Arch Pharmacol 367:509-515.
40. G-acylated imidazolylpropylguanidines. J Pharmacol Exp Ther 317:139-146.
41. 2-receptors. J Pharmacol Exp Ther 317:1262-1268.